EquiReason

EquiReason research coverage

Ascendis Pharma A/S ASND

Healthcare · Biotechnology

4quarters analysed
12SEC filings read
2segments identified
10institutional managers tracked

Where its revenue is reported

The geographies Ascendis Pharma A/S reports revenue for. How much comes from each is in the product.

  • United States
  • Europe
  • Denmark
  • Rest Of World

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements23
  • Quarterly metric series12
  • Business segments2
  • SEC filings12
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks3
  • Estimate revisions10
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series4
  • Earnings series1
  • Per-share series1
  • Operating cash flow series1
  • Guidance changesnot found
  • Margin seriesnot found
  • Cash flow seriesnot found

This page says how much of Ascendis Pharma A/S we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open ASND in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

Ascendis Pharma A/S (ASND) — research coverage | EquiReason